Table 3. Results of all patients treated per suggested dosages for at least 12 months.
| Group | Numb (drops) | Age sex F = females | Microcirculation model | PO 2 | PCO 2 | Edema score | Volume | Symptoms | Complications | Skin discoloration | Oxidative stress |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Resting flux (RF) | mL | Score 0–5 | SVT | Difference | |||||||
| 1.VENR | 83 (4) | 47; 3.2 | −38% | +11% | −9% | −1.5 | −103 | −3.9 | 0/83 | 3/83 | −31% |
| 33 F | |||||||||||
| 2.PYCNO | 122 (5) | 46; 2.6 | −43% | +13% | −10% | −2.2 | −107 | −4.3 | 0/122 | 1/122 | −39% |
| 58 F | |||||||||||
| 3.TROXER | 77 (7) | 48.2; 2,1 | −22% | +5% | −5% | −1.1 | −17 | −1.9 | 2/77 | 2/77 | −7% |
| 34 F | |||||||||||
| 4.DIO-ES | 71 (11) | 46.8; 2 | −9% | +5% | −3% | −0.6 | −33 | −1.1 | 4/71 | 7/71 | −4% |
| 33 F | |||||||||||
| 5.ANTX | 73 (8) | 47; 3.1 | −5% | +5% | −4% | −1.5 | −86 | −1.1 | 4/73 | 11/73 | −28% |
| 36 F | |||||||||||
| 6.MYRT | 77 (6) | 47.5; 2 | −6% | +8% | -6% | −0.5 | −43 | −1.3 | 5/74 | 6/77 | −9% |
| 38 F | |||||||||||
| 7.TRXER2 | 74 (7) | 48.4; 2.2 | −5% | +5% | −5% | −0.2 | −34 | −1.4 | 4/74 | 5/74 | −12% |
| 37 F | |||||||||||
| 8.ESCIN | 64 (7) | 47; 3.1 | −7% | +7% | −7% | −0.9 | −46 | −2 | 3/64 | 6/64 | −11% |
| 37 F | |||||||||||
| 9.VE-PY | 173 (12) | 47; 3,2 | −44% | +14% | −10% | −2.4 | −112 | −4.6 | 0/173 | 3/173 | −41% |
| 88 F | |||||||||||
| 10.ECOMP | 237 (18) | 47.5; 3 | −22% | +8% | −8% | −2.3 | −117 | −3.3 | 8/237 | 26/237 | −2% |
| 166 F | |||||||||||
| Total | 1,051 |
Abbreviation: SVT, superficial venous thrombosis.
Note: Clinical conditions: Varicose veins and CVI. Length: Management lasted at least four seasons.
Comparative standard management (group 10): elastic compression (stockings).
Best results underlined ( p < 0.05 in comparison with other groups).